<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02497001</url>
  </required_header>
  <id_info>
    <org_study_id>PT010006</org_study_id>
    <nct_id>NCT02497001</nct_id>
  </id_info>
  <brief_title>A Randomized, Double-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared With Symbicort® Turbuhaler® (Kronos)</brief_title>
  <acronym>KRONOS</acronym>
  <official_title>A Randomized, Double-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared With Symbicort® Turbuhaler® as an Active Control in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pearl Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pearl Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared With Symbicort®&#xD;
      Turbuhaler® in Subjects with Moderate to Very Severe Chronic Obstructive Pulmonary Disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Randomized, Double-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multi-Center Study to&#xD;
      Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared With Symbicort®&#xD;
      Turbuhaler® as an Active Control in Subjects with Moderate to Very Severe Chronic Obstructive&#xD;
      Pulmonary Disease&#xD;
&#xD;
      This study includes the following 3 sub-studies: 12-hour Pulmonary Function Test (PFT),&#xD;
      Pharmacokinetic (PK) Profile, and Hypothalamic-pituitary-adrenal Axis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 10, 2015</start_date>
  <completion_date type="Actual">January 5, 2018</completion_date>
  <primary_completion_date type="Actual">January 5, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>FEV1 AUC0-4</measure>
    <time_frame>at Week 24</time_frame>
    <description>FEV1 AUC0-4 (L) for The Efficacy Estimand (Change from baseline in forced expiratory volume in 1 second (FEV1) area under the curve from 0 to 4 hours (AUC0-4) AUC was normalized for length of follow up (e.g. typically 4 hours)).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Morning Pre-dose Trough FEV1</measure>
    <time_frame>at Week 24</time_frame>
    <description>Morning Pre-Dose Trough FEV1 (L) for The Efficacy Estimand</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Morning Pre-dose Trough FEV1</measure>
    <time_frame>over 24 Weeks</time_frame>
    <description>Morning Pre-Dose Trough FEV1 (L) for The Efficacy Estimand</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Change From Baseline in FEV1 Within 4 Hours Post-dosing</measure>
    <time_frame>at Week 24</time_frame>
    <description>Peak Change from Baseline in FEV1 (L) Within 4 Hours Post-Dose for The Efficacy Estimand</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Moderate or Severe COPD Exacerbations</measure>
    <time_frame>over 24 weeks</time_frame>
    <description>Rate of Moderate or Severe COPD Exacerbations for the Efficacy Estimand</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Achieving a Minimal Clinically Important Difference (MCID) of 4 Units or More in SGRQ Total Score (SGRQ Responders)</measure>
    <time_frame>at Week 24</time_frame>
    <description>Change from BGF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Average Daily Rescue Ventolin HFA Use</measure>
    <time_frame>over 24 Weeks</time_frame>
    <description>Change from Baseline in Mean Daily Number of Puffs of Rescue Ventolin HFA for The Efficacy Estimand</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Onset of Action on Day 1, 5 Minutes Post Dose</measure>
    <time_frame>Day 1</time_frame>
    <description>FEV1 (L) by Post-Dose Timepoint on Day 1 for The Efficacy Estimand</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Onset of Action on Day 1, 15 Minutes Post Dose</measure>
    <time_frame>Day 1</time_frame>
    <description>FEV1 (L) by Post-Dose Timepoint on Day 1 for The Efficacy Estimand</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Onset of Action on Day 1, 30 Minutes Post Dose</measure>
    <time_frame>Day 1</time_frame>
    <description>FEV1 (L) by Post-Dose Timepoint on Day 1 for The Efficacy Estimand</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Onset of Action on Day 1, 1 Hour Post Dose</measure>
    <time_frame>Day 1</time_frame>
    <description>FEV1 (L) by Post-Dose Timepoint on Day 1 for The Efficacy Estimand</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Onset of Action on Day 1, 2 Hours Post Dose</measure>
    <time_frame>Day 1</time_frame>
    <description>FEV1 (L) by Post-Dose Timepoint on Day 1 for The Efficacy Estimand</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Onset of Action on Day 1, 4 Hours Post Dose</measure>
    <time_frame>Day 1</time_frame>
    <description>FEV1 (L) by Post-Dose Timepoint on Day 1 for The Efficacy Estimand</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1902</enrollment>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>BGF MDI (PT010) 320/14.4/9.6 μg ex-actuator</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BGF MDI 320/14.4/9.6 μg,Budesonide, Glycopyrronium, Formoterol Fumarate Inhalation Aerosol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GFF MDI (PT003) 14.4/9.6 μg ex-actuator</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GFF MDI 14.4/9.6 μg ex-actuator Glycopyrronium, Formoterol Fumarate Inhalation Aerosol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BFF MDI (PT009) 320/9.6 μg ex-actuator</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BFF MDI 320/9.6 μg, Budesonide, Formoterol Fumarate Inhalation Aerosol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Symbicort</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Symbicort® Turbuhaler® (TBH) Inhalation Powder 200/6 μg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BGF MDI 320/14.4/9.6 μg</intervention_name>
    <description>Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol (PT010, BGF metered dose inhaler [MDI])</description>
    <arm_group_label>BGF MDI (PT010) 320/14.4/9.6 μg ex-actuator</arm_group_label>
    <other_name>BGF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GFF MDI (PT003) 14.4/9.6 μg</intervention_name>
    <description>Glycopyrronium and Formoterol Fumarate Inhalation Aerosol (PT003, GFF MDI)</description>
    <arm_group_label>GFF MDI (PT003) 14.4/9.6 μg ex-actuator</arm_group_label>
    <other_name>GFF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BFF MDI (PT009) 320/9.6 μg</intervention_name>
    <description>Budesonide and Formoterol Fumarate Inhalation Aerosol (PT009, BFF MDI)</description>
    <arm_group_label>BFF MDI (PT009) 320/9.6 μg ex-actuator</arm_group_label>
    <other_name>BFF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Symbicort® Turbuhaler® (TBH) Inhalation Powder</intervention_name>
    <arm_group_label>Symbicort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Given their signed written informed consent to participate.&#xD;
&#xD;
          -  Non-child bearing potential (ie, physiologically incapable of becoming pregnant,&#xD;
             including any female who is 2 years post-menopausal); or Child bearing potential, has&#xD;
             a negative serum pregnancy test at Visit 1, and agrees to acceptable contraceptive&#xD;
             methods used consistently and correctly for the duration of the study.&#xD;
&#xD;
          -  Subjects with an established clinical history of COPD as defined by the American&#xD;
             Thoracic Society (ATS)/European Respiratory Society (ERS), or other local applicable&#xD;
             guidelines.&#xD;
&#xD;
          -  Current or former smokers with a history of at least 10 pack-years of cigarette&#xD;
             smoking.&#xD;
&#xD;
          -  Forced expiratory volume in 1 second (FEV1)/Forced vital capacity (FVC) ratio must be&#xD;
             &lt;0.70 and FEV1 must be &lt;80% predicted normal value calculated using NHANES III&#xD;
             reference equations (or reference norms applicable to other regions).&#xD;
&#xD;
          -  Required COPD maintenance therapy:&#xD;
&#xD;
          -  All Subjects must have been on two or more inhaled maintenance therapies for the&#xD;
             management of their COPD for at least 6 weeks prior to Screening. Scheduled SABA&#xD;
             and/or scheduled SAMA are considered inhaled maintenance therapies&#xD;
&#xD;
        Please refer to the study protocol for the complete inclusion criteria list.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Significant diseases or conditions other than COPD, which, in the opinion of the&#xD;
             Investigator, may put the subject at risk because of participation in the study or may&#xD;
             influence either the results of the study or the subject's ability to participate in&#xD;
             the study.&#xD;
&#xD;
          -  Women who are pregnant or lactating, or are planning to become pregnant during the&#xD;
             course of the study, or women of childbearing potential who are not using an&#xD;
             acceptable method of contraception.&#xD;
&#xD;
          -  Subjects, who in the opinion of the Investigator, have a current diagnosis of asthma.&#xD;
&#xD;
          -  Subjects who have been hospitalized due to poorly controlled COPD within 3 months&#xD;
             prior to Visit 1 (Screening) or during the Screening Period&#xD;
&#xD;
          -  Subjects who have poorly controlled COPD, defined as acute worsening of COPD that&#xD;
             requires treatment with oral corticosteroids or antibiotics within 6 weeks prior to&#xD;
             Visit 1 (Screening) or during the Screening Period&#xD;
&#xD;
          -  Immune suppression or severe neurological disorders affecting control of the upper&#xD;
             airway or other risk factors that in the opinion of the Investigator would put the&#xD;
             subject at substantial risk of pneumonia.&#xD;
&#xD;
          -  Subjects with a diagnosis of narrow angle glaucoma, who, in the opinion of the&#xD;
             Investigator, have not been adequately treated.&#xD;
&#xD;
          -  Subjects who have a history of hypersensitivity to β2-agonists, budesonide or any&#xD;
             other corticosteroid components, glycopyrronium or other muscarinic anticholinergics,&#xD;
             or any other component of the IMPs.&#xD;
&#xD;
        Please refer to the study protocol for the complete inclusion criteria list.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Dorinsky, MD</last_name>
    <role>Study Director</role>
    <affiliation>Pearl Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Andalusia</city>
        <state>Alabama</state>
        <zip>36420</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jasper</city>
        <state>Alabama</state>
        <zip>35501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Peoria</city>
        <state>Arizona</state>
        <zip>85381</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gold River</city>
        <state>California</state>
        <zip>95670</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poway</city>
        <state>California</state>
        <zip>92064</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rolling Hills Estates</city>
        <state>California</state>
        <zip>90274</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95821</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33175</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33186</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ormond Beach</city>
        <state>Florida</state>
        <zip>32174</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tamarac</city>
        <state>Florida</state>
        <zip>33321</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <zip>32789</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dacula</city>
        <state>Georgia</state>
        <zip>30019</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Norcross</city>
        <state>Georgia</state>
        <zip>30071</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rincon</city>
        <state>Georgia</state>
        <zip>31326</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <zip>55435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55402</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Woodbury</city>
        <state>Minnesota</state>
        <zip>55125</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Charles</city>
        <state>Missouri</state>
        <zip>63301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gastonia</city>
        <state>North Carolina</state>
        <zip>28054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27408</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hendersonville</city>
        <state>North Carolina</state>
        <zip>28739</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mooresville</city>
        <state>North Carolina</state>
        <zip>28117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45245</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45459</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dublin</city>
        <state>Ohio</state>
        <zip>43016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Easley</city>
        <state>South Carolina</state>
        <zip>29640</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Indian Land</city>
        <state>South Carolina</state>
        <zip>29707</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rock Hill</city>
        <state>South Carolina</state>
        <zip>29732</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seneca</city>
        <state>South Carolina</state>
        <zip>29678</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Union</city>
        <state>South Carolina</state>
        <zip>29379</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Johnson City</city>
        <state>Tennessee</state>
        <zip>37601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kingwood</city>
        <state>Texas</state>
        <zip>77339</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Longview</city>
        <state>Texas</state>
        <zip>75605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Abingdon</city>
        <state>Virginia</state>
        <zip>24210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Newport News</city>
        <state>Virginia</state>
        <zip>23606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Truro</city>
        <state>Nova Scotia</state>
        <zip>B2N 1L2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L4V 1P1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sudbury</city>
        <state>Ontario</state>
        <zip>P3A 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M3J 2C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mirabel</city>
        <state>Quebec</state>
        <zip>J7J 2K8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1M 1B1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Trois-Rivières</city>
        <state>Quebec</state>
        <zip>G8T 7A1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quebec</city>
        <zip>G1W 4R4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Anqing</city>
        <zip>246003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Baotou</city>
        <zip>14010</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beijing</city>
        <zip>100048</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beijing</city>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beijing</city>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beijing</city>
        <zip>CN-100029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Changchun</city>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Changsha</city>
        <zip>410002</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Changsha</city>
        <zip>410011</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guangzhou</city>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guangzhou</city>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guangzhou</city>
        <zip>510150</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guangzhou</city>
        <zip>510180</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Haikou</city>
        <zip>570311</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hangzhou</city>
        <zip>310014</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hohhot</city>
        <zip>010017</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Huhehaote</city>
        <zip>010050</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jinan</city>
        <zip>250013</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lianyungang</city>
        <zip>222 002</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Linhai</city>
        <zip>317000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nanchang</city>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pingxiang</city>
        <zip>337055</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200092</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200120</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200240</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shengyang</city>
        <zip>110004</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shenyang</city>
        <zip>110001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shenyang</city>
        <zip>110016</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taiyuan</city>
        <zip>030001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tianjin</city>
        <zip>300052</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Urumchi</city>
        <zip>830054</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wenzhou</city>
        <zip>325027</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wuhan</city>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wuxi</city>
        <zip>320204</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Xuzhou</city>
        <zip>221006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yangzhou</city>
        <zip>225012</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yiyang Shi</city>
        <zip>413000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zhuhai</city>
        <zip>519099</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bunkyo-ku</city>
        <zip>113-8431</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chuo-ku</city>
        <zip>103-0022</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chuo-ku</city>
        <zip>103-0027</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chuo-ku</city>
        <zip>104-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Date-gun</city>
        <zip>969-1793</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fukuoka-shi</city>
        <zip>814-0180</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ginowan-shi</city>
        <zip>901-2214</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hakata-shi</city>
        <zip>812-0033</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hamamatsu-shi</city>
        <zip>430-0906</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hamamatsu-shi</city>
        <zip>430-8525</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hamamatsu-shi</city>
        <zip>434-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Higashiokitama-gun</city>
        <zip>992-0601</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Higashiosaka-shi</city>
        <zip>577-0843</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Himeji-shi</city>
        <zip>672-8064</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hirakata-shi</city>
        <zip>573-1191</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Iizuka-shi</city>
        <zip>820-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Itabashi-ku</city>
        <zip>173-8610</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Iwata-shi</city>
        <zip>438-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Izumo-shi</city>
        <zip>693-0068</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Izumo-shi</city>
        <zip>693-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kagoshima-shi</city>
        <zip>892-0847</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kahoku-gun</city>
        <zip>920-0293</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kakogawa-shi</city>
        <zip>675-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kasaoka-shi</city>
        <zip>714-0081</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kasuga-shi</city>
        <zip>816-0813</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kishiwada-shi</city>
        <zip>596-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kiyose-shi</city>
        <zip>204-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kobe-shi</city>
        <zip>650-0017</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Koga-shi</city>
        <zip>811-3195</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kurashiki-shi</city>
        <zip>711-0921</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kure-shi</city>
        <zip>737-0193</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kure-shi</city>
        <zip>737-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kyoto-shi</city>
        <zip>601-1434</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kyoto-shi</city>
        <zip>601-8206</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kyoto-shi</city>
        <zip>602-8026</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kyoto-shi</city>
        <zip>607-8062</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kyoto-shi</city>
        <zip>615-8087</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Maebashi-shi</city>
        <zip>371-0054</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Matsumoto-shi</city>
        <zip>390-0872</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Matsusaka-shi</city>
        <zip>515-8544</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Meguro-ku</city>
        <zip>153-8515</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mitaka-shi</city>
        <zip>181-8611</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mizunami-shi</city>
        <zip>509-6134</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nagaoka-shi</city>
        <zip>940-2085</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nagoya-shi</city>
        <zip>454-8502</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nagoya-shi</city>
        <zip>457-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nagoya-shi</city>
        <zip>466-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Naha-shi</city>
        <zip>902-0061</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nishishirakawa-gun</city>
        <zip>969-0213</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Obihiro-shi</city>
        <zip>080-0013</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ogaki-shi</city>
        <zip>503-8502</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oita-shi</city>
        <zip>870-0921</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oita-shi</city>
        <zip>870-0951</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Okinawa-shi</city>
        <zip>904-2143</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ookawa-shi</city>
        <zip>831-0016</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Osaka-shi</city>
        <zip>543-0035</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Osakasayama-shi</city>
        <zip>589-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Otsu-shi</city>
        <zip>520-0804</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sakai-shi</city>
        <zip>591-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sakaide-shi</city>
        <zip>762-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sapporo-shi</city>
        <zip>001-0901</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sapporo-shi</city>
        <zip>064-0915</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sendai-shi</city>
        <zip>980-8574</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sendai-shi</city>
        <zip>983-0824</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sendai-shi</city>
        <zip>984-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seto-shi</city>
        <zip>489-8642</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shinagawa-ku</city>
        <zip>142-8666</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shinjuku-ku</city>
        <zip>162-0052</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shizuoka-shi</city>
        <zip>420-8630</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Suita-shi</city>
        <zip>564-0013</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tachikawa-shi</city>
        <zip>190-0014</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Takamatsu-shi</city>
        <zip>760-8538</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toon-shi</city>
        <zip>791-0281</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toshima-ku</city>
        <zip>171-0014</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toyama-shi</city>
        <zip>930-0194</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toyama-shi</city>
        <zip>931-8533</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toyama-shi</city>
        <zip>939-8282</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yanagawa-shi</city>
        <zip>832-0059</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yokohama-shi</city>
        <zip>236-0004</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>China</country>
    <country>Japan</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=4148&amp;filename=PT010006-02_FINAL_Redacted_17MAY2018.pdf</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;amp;parentIdentifier=PT010006&amp;amp;attachmentIdentifier=e464d4a5-e38a-47b1-8e03-b8acd1cbd842&amp;amp;fileName=PT010006_SAP_v2.0_Redacted_PDFA.pdf&amp;amp;versionIdentifier=</url>
    <description>Related Info</description>
  </link>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>July 8, 2015</study_first_submitted>
  <study_first_submitted_qc>July 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2015</study_first_posted>
  <results_first_submitted>March 26, 2020</results_first_submitted>
  <results_first_submitted_qc>December 23, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 24, 2020</results_first_posted>
  <disposition_first_submitted>February 14, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>February 14, 2019</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">February 18, 2019</disposition_first_posted>
  <last_update_submitted>December 23, 2020</last_update_submitted>
  <last_update_submitted_qc>December 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 9, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/01/NCT02497001/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 25, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/01/NCT02497001/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted at 208 sites in four countries, from August 2015 until January 2018. The entire study period could take up to a maximum of 30 weeks.</recruitment_details>
      <pre_assignment_details>Subjects were randomized in a 2:2:1:1 scheme.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>BGF MDI 320/14.4/9.6 ug</title>
          <description>Budesonide Glycopyrronium Formoterol Fumarate Metered Dose Inhalation 320/14.4/9.6 ug</description>
        </group>
        <group group_id="P2">
          <title>GFF MDI 14.4/9.6 ug</title>
          <description>Glycopyrronium Formoterol Fumarate Metered Dose Inhalation 14.4/9.6 ug</description>
        </group>
        <group group_id="P3">
          <title>BFF MDI 320/9.6 ug</title>
          <description>Budesonide Formoterol Fumarate Metered Dose Inhalation 320/9.6 ug</description>
        </group>
        <group group_id="P4">
          <title>Symbicort TBH 400/12 ug</title>
          <description>Symbicort Turbuhaler 400/12 ug</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="640"/>
                <participants group_id="P2" count="627"/>
                <participants group_id="P3" count="316"/>
                <participants group_id="P4" count="319"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="566"/>
                <participants group_id="P2" count="524"/>
                <participants group_id="P3" count="266"/>
                <participants group_id="P4" count="278"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="74"/>
                <participants group_id="P2" count="103"/>
                <participants group_id="P3" count="50"/>
                <participants group_id="P4" count="41"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="37"/>
                <participants group_id="P3" count="19"/>
                <participants group_id="P4" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>subjects that were not treated</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Major Protocol Deviation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>mITT - Modified Intent to Treat</population>
      <group_list>
        <group group_id="B1">
          <title>BGF MDI 320/14.4/9.6 ug</title>
          <description>Budesonide Glycopyrronium Formoterol Fumarate Metered Dose Inhalation 320/14.4/9.6 ug</description>
        </group>
        <group group_id="B2">
          <title>GFF MDI 14.4/9.6 ug</title>
          <description>Glycopyrronium Formoterol Fumarate Metered Dose Inhalation 14.4/9.6 ug</description>
        </group>
        <group group_id="B3">
          <title>BFF MDI 320/9.6 ug</title>
          <description>Budesonide Formoterol Fumarate Metered Dose Inhalation 320/9.6 ug</description>
        </group>
        <group group_id="B4">
          <title>Symbicort TBH 400/12 ug</title>
          <description>Symbicort Turbuhaler 400/12 ug</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="639"/>
            <count group_id="B2" value="625"/>
            <count group_id="B3" value="314"/>
            <count group_id="B4" value="318"/>
            <count group_id="B5" value="1896"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>mITT</population>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.9" spread="7.8"/>
                    <measurement group_id="B2" value="65.1" spread="7.7"/>
                    <measurement group_id="B3" value="65.2" spread="7.2"/>
                    <measurement group_id="B4" value="65.9" spread="7.7"/>
                    <measurement group_id="B5" value="65.2" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="179"/>
                    <measurement group_id="B2" value="195"/>
                    <measurement group_id="B3" value="90"/>
                    <measurement group_id="B4" value="82"/>
                    <measurement group_id="B5" value="546"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="460"/>
                    <measurement group_id="B2" value="430"/>
                    <measurement group_id="B3" value="224"/>
                    <measurement group_id="B4" value="236"/>
                    <measurement group_id="B5" value="1350"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <population>mITT</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="623"/>
                    <measurement group_id="B2" value="611"/>
                    <measurement group_id="B3" value="305"/>
                    <measurement group_id="B4" value="312"/>
                    <measurement group_id="B5" value="1851"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <population>mITT</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="284"/>
                    <measurement group_id="B2" value="285"/>
                    <measurement group_id="B3" value="142"/>
                    <measurement group_id="B4" value="141"/>
                    <measurement group_id="B5" value="852"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="90"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="329"/>
                    <measurement group_id="B2" value="301"/>
                    <measurement group_id="B3" value="157"/>
                    <measurement group_id="B4" value="163"/>
                    <measurement group_id="B5" value="950"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>FEV1 AUC0-4</title>
        <description>FEV1 AUC0-4 (L) for The Efficacy Estimand (Change from baseline in forced expiratory volume in 1 second (FEV1) area under the curve from 0 to 4 hours (AUC0-4) AUC was normalized for length of follow up (e.g. typically 4 hours)).</description>
        <time_frame>at Week 24</time_frame>
        <population>mITT population total numbers may vary based on predefined subject exclusions prior to study unblinding</population>
        <group_list>
          <group group_id="O1">
            <title>BGF MDI 320/14.4/9.6 μg</title>
            <description>Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol (PT010, BGF metered dose inhaler [MDI])</description>
          </group>
          <group group_id="O2">
            <title>GFF MDI (PT003) 14.4/9.6 μg</title>
            <description>Glycopyrronium and Formoterol Fumarate Inhalation Aerosol (PT003, GFF MDI)</description>
          </group>
          <group group_id="O3">
            <title>BFF MDI (PT009) 320/9.6 μg</title>
            <description>Budesonide and Formoterol Fumarate Inhalation Aerosol (PT009, BFF MDI)</description>
          </group>
          <group group_id="O4">
            <title>Symbicort®</title>
            <description>Symbicort® Turbuhaler® (TBH) Inhalation Powder</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 AUC0-4</title>
          <description>FEV1 AUC0-4 (L) for The Efficacy Estimand (Change from baseline in forced expiratory volume in 1 second (FEV1) area under the curve from 0 to 4 hours (AUC0-4) AUC was normalized for length of follow up (e.g. typically 4 hours)).</description>
          <population>mITT population total numbers may vary based on predefined subject exclusions prior to study unblinding</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="436"/>
                <count group_id="O2" value="403"/>
                <count group_id="O3" value="201"/>
                <count group_id="O4" value="211"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.292" lower_limit="0.271" upper_limit="0.314"/>
                    <measurement group_id="O2" value="0.288" lower_limit="0.266" upper_limit="0.310"/>
                    <measurement group_id="O3" value="0.177" lower_limit="0.146" upper_limit="0.207"/>
                    <measurement group_id="O4" value="0.189" lower_limit="0.160" upper_limit="0.219"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Morning Pre-dose Trough FEV1</title>
        <description>Morning Pre-Dose Trough FEV1 (L) for The Efficacy Estimand</description>
        <time_frame>at Week 24</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>BGF MDI 320/14.4/9.6 μg</title>
            <description>Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol (PT010, BGF metered dose inhaler [MDI])</description>
          </group>
          <group group_id="O2">
            <title>GFF MDI (PT003) 14.4/9.6 μg</title>
            <description>Glycopyrronium and Formoterol Fumarate Inhalation Aerosol (PT003, GFF MDI)</description>
          </group>
          <group group_id="O3">
            <title>BFF MDI (PT009) 320/9.6 μg</title>
            <description>Budesonide and Formoterol Fumarate Inhalation Aerosol (PT009, BFF MDI)</description>
          </group>
          <group group_id="O4">
            <title>Symbicort®</title>
            <description>Symbicort® Turbuhaler® (TBH) Inhalation Powder</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Morning Pre-dose Trough FEV1</title>
          <description>Morning Pre-Dose Trough FEV1 (L) for The Efficacy Estimand</description>
          <population>mITT</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="565"/>
                <count group_id="O2" value="522"/>
                <count group_id="O3" value="266"/>
                <count group_id="O4" value="276"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.124" lower_limit="0.108" upper_limit="0.140"/>
                    <measurement group_id="O2" value="0.111" lower_limit="0.094" upper_limit="0.127"/>
                    <measurement group_id="O3" value="0.050" lower_limit="0.027" upper_limit="0.072"/>
                    <measurement group_id="O4" value="0.062" lower_limit="0.039" upper_limit="0.084"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Morning Pre-dose Trough FEV1</title>
        <description>Morning Pre-Dose Trough FEV1 (L) for The Efficacy Estimand</description>
        <time_frame>over 24 Weeks</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>BGF MDI 320/14.4/9.6 μg</title>
            <description>Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol (PT010, BGF metered dose inhaler [MDI])</description>
          </group>
          <group group_id="O2">
            <title>GFF MDI (PT003) 14.4/9.6 μg</title>
            <description>Glycopyrronium and Formoterol Fumarate Inhalation Aerosol (PT003, GFF MDI)</description>
          </group>
          <group group_id="O3">
            <title>BFF MDI (PT009) 320/9.6 μg</title>
            <description>Budesonide and Formoterol Fumarate Inhalation Aerosol (PT009, BFF MDI)</description>
          </group>
          <group group_id="O4">
            <title>Symbicort®</title>
            <description>Symbicort® Turbuhaler® (TBH) Inhalation Powder</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Morning Pre-dose Trough FEV1</title>
          <description>Morning Pre-Dose Trough FEV1 (L) for The Efficacy Estimand</description>
          <population>mITT</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="622"/>
                <count group_id="O2" value="601"/>
                <count group_id="O3" value="300"/>
                <count group_id="O4" value="301"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.147" lower_limit="0.134" upper_limit="0.159"/>
                    <measurement group_id="O2" value="0.125" lower_limit="0.112" upper_limit="0.137"/>
                    <measurement group_id="O3" value="0.073" lower_limit="0.055" upper_limit="0.091"/>
                    <measurement group_id="O4" value="0.088" lower_limit="0.070" upper_limit="0.105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Change From Baseline in FEV1 Within 4 Hours Post-dosing</title>
        <description>Peak Change from Baseline in FEV1 (L) Within 4 Hours Post-Dose for The Efficacy Estimand</description>
        <time_frame>at Week 24</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>BGF MDI 320/14.4/9.6 μg</title>
            <description>Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol (PT010, BGF metered dose inhaler [MDI])</description>
          </group>
          <group group_id="O2">
            <title>GFF MDI (PT003) 14.4/9.6 μg</title>
            <description>Glycopyrronium and Formoterol Fumarate Inhalation Aerosol (PT003, GFF MDI)</description>
          </group>
          <group group_id="O3">
            <title>BFF MDI (PT009) 320/9.6 μg</title>
            <description>Budesonide and Formoterol Fumarate Inhalation Aerosol (PT009, BFF MDI)</description>
          </group>
          <group group_id="O4">
            <title>Symbicort®</title>
            <description>Symbicort® Turbuhaler® (TBH) Inhalation Powder</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Change From Baseline in FEV1 Within 4 Hours Post-dosing</title>
          <description>Peak Change from Baseline in FEV1 (L) Within 4 Hours Post-Dose for The Efficacy Estimand</description>
          <population>mITT</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="436"/>
                <count group_id="O2" value="403"/>
                <count group_id="O3" value="201"/>
                <count group_id="O4" value="211"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.370" lower_limit="0.348" upper_limit="0.393"/>
                    <measurement group_id="O2" value="0.361" lower_limit="0.338" upper_limit="0.384"/>
                    <measurement group_id="O3" value="0.253" lower_limit="0.221" upper_limit="0.284"/>
                    <measurement group_id="O4" value="0.264" lower_limit="0.233" upper_limit="0.295"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Moderate or Severe COPD Exacerbations</title>
        <description>Rate of Moderate or Severe COPD Exacerbations for the Efficacy Estimand</description>
        <time_frame>over 24 weeks</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>BGF MDI 320/14.4/9.6 μg</title>
            <description>Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol (PT010, BGF metered dose inhaler [MDI])</description>
          </group>
          <group group_id="O2">
            <title>GFF MDI (PT003) 14.4/9.6 μg</title>
            <description>Glycopyrronium and Formoterol Fumarate Inhalation Aerosol (PT003, GFF MDI)</description>
          </group>
          <group group_id="O3">
            <title>BFF MDI (PT009) 320/9.6 μg</title>
            <description>Budesonide and Formoterol Fumarate Inhalation Aerosol (PT009, BFF MDI)</description>
          </group>
          <group group_id="O4">
            <title>Symbicort®</title>
            <description>Symbicort® Turbuhaler® (TBH) Inhalation Powder</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Moderate or Severe COPD Exacerbations</title>
          <description>Rate of Moderate or Severe COPD Exacerbations for the Efficacy Estimand</description>
          <population>mITT</population>
          <units>Exacerbations</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="157"/>
                <count group_id="O3" value="65"/>
                <count group_id="O4" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.46" spread="0.05"/>
                    <measurement group_id="O2" value="0.95" spread="0.09"/>
                    <measurement group_id="O3" value="0.56" spread="0.08"/>
                    <measurement group_id="O4" value="0.55" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects Achieving a Minimal Clinically Important Difference (MCID) of 4 Units or More in SGRQ Total Score (SGRQ Responders)</title>
        <description>Change from BGF</description>
        <time_frame>at Week 24</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>GFF MDI (PT003) 14.4/9.6 μg</title>
            <description>Glycopyrronium and Formoterol Fumarate Inhalation Aerosol (PT003, GFF MDI)</description>
          </group>
          <group group_id="O2">
            <title>BFF MDI (PT009) 320/9.6 μg</title>
            <description>Budesonide and Formoterol Fumarate Inhalation Aerosol (PT009, BFF MDI)</description>
          </group>
          <group group_id="O3">
            <title>Symbicort®</title>
            <description>Symbicort® Turbuhaler® (TBH) Inhalation Powder</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Achieving a Minimal Clinically Important Difference (MCID) of 4 Units or More in SGRQ Total Score (SGRQ Responders)</title>
          <description>Change from BGF</description>
          <population>mITT</population>
          <units>Percentage</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="625"/>
                <count group_id="O2" value="314"/>
                <count group_id="O3" value="318"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.06" lower_limit="0.30" upper_limit="11.82"/>
                    <measurement group_id="O2" value="6.43" lower_limit="-0.62" upper_limit="13.47"/>
                    <measurement group_id="O3" value="8.23" lower_limit="1.23" upper_limit="15.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Average Daily Rescue Ventolin HFA Use</title>
        <description>Change from Baseline in Mean Daily Number of Puffs of Rescue Ventolin HFA for The Efficacy Estimand</description>
        <time_frame>over 24 Weeks</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>BGF MDI 320/14.4/9.6 μg</title>
            <description>Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol (PT010, BGF metered dose inhaler [MDI])</description>
          </group>
          <group group_id="O2">
            <title>GFF MDI (PT003) 14.4/9.6 μg</title>
            <description>Glycopyrronium and Formoterol Fumarate Inhalation Aerosol (PT003, GFF MDI)</description>
          </group>
          <group group_id="O3">
            <title>BFF MDI (PT009) 320/9.6 μg</title>
            <description>Budesonide and Formoterol Fumarate Inhalation Aerosol (PT009, BFF MDI)</description>
          </group>
          <group group_id="O4">
            <title>Symbicort®</title>
            <description>Symbicort® Turbuhaler® (TBH) Inhalation Powder</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Average Daily Rescue Ventolin HFA Use</title>
          <description>Change from Baseline in Mean Daily Number of Puffs of Rescue Ventolin HFA for The Efficacy Estimand</description>
          <population>mITT</population>
          <units>Puffs</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
                <count group_id="O2" value="155"/>
                <count group_id="O3" value="269"/>
                <count group_id="O4" value="233"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" lower_limit="-1.6" upper_limit="-1.1"/>
                    <measurement group_id="O2" value="-1.1" lower_limit="-1.3" upper_limit="-0.8"/>
                    <measurement group_id="O3" value="-1.1" lower_limit="-1.5" upper_limit="-0.8"/>
                    <measurement group_id="O4" value="-1.6" lower_limit="-1.9" upper_limit="-1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Onset of Action on Day 1, 5 Minutes Post Dose</title>
        <description>FEV1 (L) by Post-Dose Timepoint on Day 1 for The Efficacy Estimand</description>
        <time_frame>Day 1</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>BGF MDI 320/14.4/9.6 μg</title>
            <description>Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol (PT010, BGF metered dose inhaler [MDI])</description>
          </group>
          <group group_id="O2">
            <title>GFF MDI (PT003) 14.4/9.6 μg</title>
            <description>Glycopyrronium and Formoterol Fumarate Inhalation Aerosol (PT003, GFF MDI)</description>
          </group>
          <group group_id="O3">
            <title>BFF MDI (PT009) 320/9.6 μg</title>
            <description>Budesonide and Formoterol Fumarate Inhalation Aerosol (PT009, BFF MDI)</description>
          </group>
          <group group_id="O4">
            <title>Symbicort®</title>
            <description>Symbicort® Turbuhaler® (TBH) Inhalation Powder</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Onset of Action on Day 1, 5 Minutes Post Dose</title>
          <description>FEV1 (L) by Post-Dose Timepoint on Day 1 for The Efficacy Estimand</description>
          <population>mITT</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="429"/>
                <count group_id="O2" value="417"/>
                <count group_id="O3" value="220"/>
                <count group_id="O4" value="210"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.181" lower_limit="0.169" upper_limit="0.192"/>
                    <measurement group_id="O2" value="0.194" lower_limit="0.182" upper_limit="0.205"/>
                    <measurement group_id="O3" value="0.167" lower_limit="0.152" upper_limit="0.182"/>
                    <measurement group_id="O4" value="0.163" lower_limit="0.148" upper_limit="0.178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Onset of Action on Day 1, 15 Minutes Post Dose</title>
        <description>FEV1 (L) by Post-Dose Timepoint on Day 1 for The Efficacy Estimand</description>
        <time_frame>Day 1</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>BGF MDI 320/14.4/9.6 μg</title>
            <description>Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol (PT010, BGF metered dose inhaler [MDI])</description>
          </group>
          <group group_id="O2">
            <title>GFF MDI (PT003) 14.4/9.6 μg</title>
            <description>Glycopyrronium and Formoterol Fumarate Inhalation Aerosol (PT003, GFF MDI)</description>
          </group>
          <group group_id="O3">
            <title>BFF MDI (PT009) 320/9.6 μg</title>
            <description>Budesonide and Formoterol Fumarate Inhalation Aerosol (PT009, BFF MDI)</description>
          </group>
          <group group_id="O4">
            <title>Symbicort®</title>
            <description>Symbicort® Turbuhaler® (TBH) Inhalation Powder</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Onset of Action on Day 1, 15 Minutes Post Dose</title>
          <description>FEV1 (L) by Post-Dose Timepoint on Day 1 for The Efficacy Estimand</description>
          <population>mITT</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="484"/>
                <count group_id="O2" value="470"/>
                <count group_id="O3" value="238"/>
                <count group_id="O4" value="238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.217" lower_limit="0.205" upper_limit="0.230"/>
                    <measurement group_id="O2" value="0.230" lower_limit="0.218" upper_limit="0.243"/>
                    <measurement group_id="O3" value="0.197" lower_limit="0.180" upper_limit="0.213"/>
                    <measurement group_id="O4" value="0.190" lower_limit="0.174" upper_limit="0.207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Onset of Action on Day 1, 30 Minutes Post Dose</title>
        <description>FEV1 (L) by Post-Dose Timepoint on Day 1 for The Efficacy Estimand</description>
        <time_frame>Day 1</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>BGF MDI 320/14.4/9.6 μg</title>
            <description>Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol (PT010, BGF metered dose inhaler [MDI])</description>
          </group>
          <group group_id="O2">
            <title>GFF MDI (PT003) 14.4/9.6 μg</title>
            <description>Glycopyrronium and Formoterol Fumarate Inhalation Aerosol (PT003, GFF MDI)</description>
          </group>
          <group group_id="O3">
            <title>BFF MDI (PT009) 320/9.6 μg</title>
            <description>Budesonide and Formoterol Fumarate Inhalation Aerosol (PT009, BFF MDI)</description>
          </group>
          <group group_id="O4">
            <title>Symbicort®</title>
            <description>Symbicort® Turbuhaler® (TBH) Inhalation Powder</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Onset of Action on Day 1, 30 Minutes Post Dose</title>
          <description>FEV1 (L) by Post-Dose Timepoint on Day 1 for The Efficacy Estimand</description>
          <population>mITT</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="490"/>
                <count group_id="O2" value="474"/>
                <count group_id="O3" value="242"/>
                <count group_id="O4" value="238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.236" lower_limit="0.223" upper_limit="0.249"/>
                    <measurement group_id="O2" value="0.255" lower_limit="0.242" upper_limit="0.268"/>
                    <measurement group_id="O3" value="0.213" lower_limit="0.195" upper_limit="0.230"/>
                    <measurement group_id="O4" value="0.208" lower_limit="0.190" upper_limit="0.225"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Onset of Action on Day 1, 1 Hour Post Dose</title>
        <description>FEV1 (L) by Post-Dose Timepoint on Day 1 for The Efficacy Estimand</description>
        <time_frame>Day 1</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>BGF MDI 320/14.4/9.6 μg</title>
            <description>Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol (PT010, BGF metered dose inhaler [MDI])</description>
          </group>
          <group group_id="O2">
            <title>GFF MDI (PT003) 14.4/9.6 μg</title>
            <description>Glycopyrronium and Formoterol Fumarate Inhalation Aerosol (PT003, GFF MDI)</description>
          </group>
          <group group_id="O3">
            <title>BFF MDI (PT009) 320/9.6 μg</title>
            <description>Budesonide and Formoterol Fumarate Inhalation Aerosol (PT009, BFF MDI)</description>
          </group>
          <group group_id="O4">
            <title>Symbicort®</title>
            <description>Symbicort® Turbuhaler® (TBH) Inhalation Powder</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Onset of Action on Day 1, 1 Hour Post Dose</title>
          <description>FEV1 (L) by Post-Dose Timepoint on Day 1 for The Efficacy Estimand</description>
          <population>mITT</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="497"/>
                <count group_id="O2" value="481"/>
                <count group_id="O3" value="244"/>
                <count group_id="O4" value="245"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.268" lower_limit="0.254" upper_limit="0.282"/>
                    <measurement group_id="O2" value="0.282" lower_limit="0.268" upper_limit="0.296"/>
                    <measurement group_id="O3" value="0.228" lower_limit="0.208" upper_limit="0.247"/>
                    <measurement group_id="O4" value="0.232" lower_limit="0.213" upper_limit="0.251"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Onset of Action on Day 1, 2 Hours Post Dose</title>
        <description>FEV1 (L) by Post-Dose Timepoint on Day 1 for The Efficacy Estimand</description>
        <time_frame>Day 1</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>BGF MDI 320/14.4/9.6 μg</title>
            <description>Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol (PT010, BGF metered dose inhaler [MDI])</description>
          </group>
          <group group_id="O2">
            <title>GFF MDI (PT003) 14.4/9.6 μg</title>
            <description>Glycopyrronium and Formoterol Fumarate Inhalation Aerosol (PT003, GFF MDI)</description>
          </group>
          <group group_id="O3">
            <title>BFF MDI (PT009) 320/9.6 μg</title>
            <description>Budesonide and Formoterol Fumarate Inhalation Aerosol (PT009, BFF MDI)</description>
          </group>
          <group group_id="O4">
            <title>Symbicort®</title>
            <description>Symbicort® Turbuhaler® (TBH) Inhalation Powder</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Onset of Action on Day 1, 2 Hours Post Dose</title>
          <description>FEV1 (L) by Post-Dose Timepoint on Day 1 for The Efficacy Estimand</description>
          <population>mITT</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="494"/>
                <count group_id="O2" value="480"/>
                <count group_id="O3" value="243"/>
                <count group_id="O4" value="246"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.281" lower_limit="0.266" upper_limit="0.295"/>
                    <measurement group_id="O2" value="0.292" lower_limit="0.277" upper_limit="0.307"/>
                    <measurement group_id="O3" value="0.241" lower_limit="0.220" upper_limit="0.261"/>
                    <measurement group_id="O4" value="0.244" lower_limit="0.224" upper_limit="0.265"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Onset of Action on Day 1, 4 Hours Post Dose</title>
        <description>FEV1 (L) by Post-Dose Timepoint on Day 1 for The Efficacy Estimand</description>
        <time_frame>Day 1</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>BGF MDI 320/14.4/9.6 μg</title>
            <description>Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol (PT010, BGF metered dose inhaler [MDI])</description>
          </group>
          <group group_id="O2">
            <title>GFF MDI (PT003) 14.4/9.6 μg</title>
            <description>Glycopyrronium and Formoterol Fumarate Inhalation Aerosol (PT003, GFF MDI)</description>
          </group>
          <group group_id="O3">
            <title>BFF MDI (PT009) 320/9.6 μg</title>
            <description>Budesonide and Formoterol Fumarate Inhalation Aerosol (PT009, BFF MDI)</description>
          </group>
          <group group_id="O4">
            <title>Symbicort®</title>
            <description>Symbicort® Turbuhaler® (TBH) Inhalation Powder</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Onset of Action on Day 1, 4 Hours Post Dose</title>
          <description>FEV1 (L) by Post-Dose Timepoint on Day 1 for The Efficacy Estimand</description>
          <population>mITT</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="491"/>
                <count group_id="O2" value="477"/>
                <count group_id="O3" value="243"/>
                <count group_id="O4" value="244"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.276" lower_limit="0.260" upper_limit="0.292"/>
                    <measurement group_id="O2" value="0.278" lower_limit="0.262" upper_limit="0.294"/>
                    <measurement group_id="O3" value="0.234" lower_limit="0.213" upper_limit="0.256"/>
                    <measurement group_id="O4" value="0.247" lower_limit="0.225" upper_limit="0.268"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious Adverse events were collected from the time subject signed Informed Consent to the time of the final follow-up telephone call. Adverse Events were collected from the time subject was randomized.</time_frame>
      <desc>The Safety Population was defined as all subjects who were randomized to treatment and received at least 1 dose of the study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>BGF MDI 320/14.4/9.6 ug</title>
          <description>Budesonide Glycopyrronium Formoterol Fumarate Metered Dose Inhalation 320/14.4/9.6 ug</description>
        </group>
        <group group_id="E2">
          <title>GFF MDI 14.4/9.6 ug</title>
          <description>Glycopyrronium Formoterol Fumarate Metered Dose Inhalation 14.4/9.6 ug</description>
        </group>
        <group group_id="E3">
          <title>BFF MDI 320/9.6 ug</title>
          <description>Budesonide Formoterol Fumarate Metered Dose Inhalation 320/9.6 ug</description>
        </group>
        <group group_id="E4">
          <title>Symbicort TBH 400/12 ug</title>
          <description>Symbicort Turbuhaler 400/12 ug</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="639"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="625"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="639"/>
                <counts group_id="E2" subjects_affected="68" subjects_at_risk="625"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="29" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="625"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title vocab="medDRA">Coronary artery disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Atrial fibrilation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Cardiac failure tamponade</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="625"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Intestinal polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Large intestinal polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Systemic inflammatory response syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Hepatic cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="639"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="625"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Dengue ferver</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Diverticulitits</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Gastritis viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Lymphangitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Meningitis viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Pulmonary contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Respiratory fume inhalation disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Road traffic accident6</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Electrocardiogram T wave inversion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title vocab="nedDRA">Prostate cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of lung</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Acute myeloid leukemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Brain cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Colorectal cancer metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm of thymus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Metasteses of liver</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Metasteses to lung</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Metastases to spine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Papilloma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Urethral cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Central nervous system lesion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Cerebral ischeamia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Cerebrovascular insufficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Siezure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Myelopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Delerium</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Ureterolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="639"/>
                <counts group_id="E2" events="41" subjects_affected="32" subjects_at_risk="625"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="314"/>
                <counts group_id="E4" events="16" subjects_affected="13" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="639"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Lung infiltration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Pulmonary mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arterial stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="625"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Iliac artery occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="625"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="126" subjects_at_risk="639"/>
                <counts group_id="E2" subjects_affected="84" subjects_at_risk="625"/>
                <counts group_id="E3" subjects_affected="59" subjects_at_risk="314"/>
                <counts group_id="E4" subjects_affected="55" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitits</sub_title>
                <counts group_id="E1" events="61" subjects_affected="49" subjects_at_risk="639"/>
                <counts group_id="E2" events="48" subjects_affected="41" subjects_at_risk="625"/>
                <counts group_id="E3" events="30" subjects_affected="26" subjects_at_risk="314"/>
                <counts group_id="E4" events="32" subjects_affected="30" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Infection</sub_title>
                <counts group_id="E1" events="77" subjects_affected="65" subjects_at_risk="639"/>
                <counts group_id="E2" events="41" subjects_affected="37" subjects_at_risk="625"/>
                <counts group_id="E3" events="18" subjects_affected="18" subjects_at_risk="314"/>
                <counts group_id="E4" events="23" subjects_affected="22" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle Spasms</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="639"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="625"/>
                <counts group_id="E3" events="18" subjects_affected="17" subjects_at_risk="314"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Drafts of any and all publications or presentations of this study must be submitted at least 30 days prior to submission for publication or presentation to Pearl Therapeutics for review, approval, and to ensure consistency. Pearl Therapeutics has the right to request appropriate modification to correct facts and to represent it's opinions, or the opinions of the publication committee, if these differ with the proposed publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pearl Therapeutics Inc.</name_or_title>
      <organization>Pearl Therapeutics Inc.</organization>
      <phone>1-877-240-9479</phone>
      <email>information.center@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

